Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Change in Inventory (2018 - 2025)

10x Genomics' Change in Inventory history spans 8 years, with the latest figure at -$5.6 million for Q4 2025.

  • For Q4 2025, Change in Inventory rose 41.97% year-over-year to -$5.6 million; the TTM value through Dec 2025 reached -$28.0 million, down 385.91%, while the annual FY2025 figure was -$28.0 million, 385.91% down from the prior year.
  • Change in Inventory for Q4 2025 was -$5.6 million at 10x Genomics, up from -$7.3 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $9.9 million in Q1 2024 and bottomed at -$9.6 million in Q4 2024.
  • The 5-year median for Change in Inventory is $2.8 million (2022), against an average of $1.3 million.
  • The largest annual shift saw Change in Inventory tumbled 632.08% in 2023 before it soared 2113.14% in 2024.
  • A 5-year view of Change in Inventory shows it stood at $8.8 million in 2021, then plummeted by 83.71% to $1.4 million in 2022, then crashed by 632.08% to -$7.6 million in 2023, then decreased by 26.33% to -$9.6 million in 2024, then surged by 41.97% to -$5.6 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Change in Inventory are -$5.6 million (Q4 2025), -$7.3 million (Q3 2025), and -$7.0 million (Q2 2025).